Go online to PeerView.com/FJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances
Upload Date: Jul 20, 2021
There are currently no snippets from Jacob Sands, MD - Making the Most of Treatment Advances in SCLC: New Standards, Practicalities of Care, and Hope on the Horizon.
Snippets are an easy way to highlight your favorite soundbite from any piece of
audio and share with friends, or make a trailer for PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Go online to PeerView.com/FJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting, a novel transcription inhibitor has expanded very limited options in the second-line setting, and a unique myeloprotective agent has become available that can decrease the incidence of chemotherapy-induced myelosuppression in patients with SCLC. These developments have provided new hope to patients with SCLC, but they have also increased the urgency to diagnose and treat SCLC in a timely manner to ensure patients can derive benefits from these therapies. This activity based on a live web broadcast focuses on evidence and practical guidance to help clinicians make the most of the latest treatment advances in SCLC. Essential data and best-practice recommendations are framed with cases, to illustrate how to integrate the new therapeutic options into clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Describe the challenges, disparities, and latest treatment advances that have led to improvements in outcomes in small cell lung cancer (SCLC), Review the latest efficacy, safety, and biomarker data from clinical trials evaluating immune checkpoint inhibition, transcription inhibition, and other novel treatment approaches and combinations in SCLC, Apply best practices for collaboration and coordination of care among the multidisciplinary lung cancer team to optimize diagnosis, assessment, and rapid initiation of treatment, and minimize treatment-related toxicities in all patients with SCLC, Develop individualized treatment plans for patients with SCLC throughout the disease continuum in the context of clinical practice or clinical trial participation.